Maven Securities LTD Buys Shares of 50,000 Bicara Therapeutics Inc. (NASDAQ:BCAX)

Maven Securities LTD bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the company's stock, valued at approximately $1,274,000. Maven Securities LTD owned about 0.10% of Bicara Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cinctive Capital Management LP acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at about $229,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at about $462,000. The Manufacturers Life Insurance Company acquired a new stake in Bicara Therapeutics during the third quarter worth about $582,000. Walleye Capital LLC bought a new position in Bicara Therapeutics in the third quarter worth about $809,000. Finally, Iron Triangle Partners LP acquired a new position in Bicara Therapeutics in the third quarter valued at approximately $5,094,000.

Bicara Therapeutics Trading Down 2.1 %

Shares of BCAX stock traded down $0.41 during midday trading on Thursday, reaching $19.54. 220,374 shares of the company were exchanged, compared to its average volume of 353,903. The business has a 50 day simple moving average of $21.82. Bicara Therapeutics Inc. has a 12 month low of $17.41 and a 12 month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, equities research analysts predict that Bicara Therapeutics Inc. will post -2.89 earnings per share for the current year.

Insider Buying and Selling at Bicara Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the company's stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the purchase, the director now owns 4,303,418 shares of the company's stock, valued at $77,461,524. This trade represents a 74.20 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder James E. Flynn acquired 70,000 shares of the business's stock in a transaction on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the acquisition, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 8.46 % increase in their position. The disclosure for this purchase can be found here.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BCAX. RODMAN&RENSHAW upgraded Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. Rodman & Renshaw started coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 target price on the stock. Morgan Stanley started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price target for the company. TD Cowen initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a "buy" rating on the stock. Finally, Cantor Fitzgerald began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating on the stock. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $43.33.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.